Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA-Reference-Cited by-同舟云学术

Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA

Published:2021-12-06 Issue: Volume: Page:
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Milano Gerard¹²^ORCID,Gal Jocelyn²³^ORCID,Creisson Anne⁴,Chamorey Emmanuel²³^ORCID

Affiliation:

1. Centre Antoine Lacassagne, Unité Propre de Recherche 7497, Université Côte d’Azur, 06100, Nice, France

2. Centre Antoine Lacassagne, UNS EA 7497 Nice University, 33 Avenue de Valombrose, 06189, Nice, France

3. Epidemiology & Biostatistics Department, Centre Antoine Lacassagne, University Côte d’Azur, 33 Avenue de Valombrose, 06189, Nice, France

4. Medical oncology Department, Centre Antoine Lacassagne, University Côte d’Azur, 33 Avenue de Valombrose, 06189, Nice, France

Abstract

While tolerance to COVID-19 vaccination is considered satisfactory, a phenomenon of myocarditis, although rare, is becoming a safety concern in mRNA COVID-19 vaccination. The presence of low residual levels of double-strand RNA (dsRNA) has been reported in mRNA COVID-19 vaccine preparations. dsRNA is a known inducer of immune-inflammatory reactions. dsRNA present in vaccine nanoparticles may be suspected to be at the origin of the still unexplained cases of myocarditis.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2021-0280

Reference32 articles.

1. Host Polymorphisms May Impact SARS-CoV-2 Infectivity

2. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells

3. How SARS-CoV-2 first adapted in humans

4. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

5. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems;Vaccines;2024-08-01

2. Incidence and management of the main serious adverse events reported after COVID‐19 vaccination;Pharmacology Research & Perspectives;2024-06

3. Comprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production;Scientific Reports;2024-04-26

4. The Epidemiology of COVID-19 Vaccine-Induced Myocarditis;Advances in Medicine;2024-04-18

5. COVID-19 mRNA vaccine-related myocarditis: A PRISMA systematic review, imaging approach and differential diagnoses;Radiology Case Reports;2024-03